Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned…
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated…
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2…
VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the…
BELO HORIZONTE, Brazil, May 12, 2025 (GLOBE NEWSWIRE) -- Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the leading financial super…
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12,…
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…
BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical…
First Quarter Chubbies Segment Sales up 43.9% and Solo Stove Sales Down, as Expected, to Realign Go-to-Market Strategy; Solid Evidence…
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline…
This website uses cookies.